Mass General Brigham Tests AI Tool to Assess Cancer Patients' Treatment Eligibility
Doctors at Mass General Brigham are using facial photographs and artificial intelligence to determine which cancer patients can tolerate intensive therapies, according to Dr. Ray Mak. The tool, called FaceAge, analyzes patient images alongside existing risk calculators to inform treatment decisions.
The approach addresses a practical problem in oncology: clinicians need reliable ways to predict whether a patient's overall health will sustain aggressive cancer treatment. FaceAge generates data that feeds into existing risk assessment protocols rather than replacing them.
The tool works by analyzing facial features in photographs. Researchers trained it to recognize physical markers associated with age-related health status and treatment tolerance.
Where Healthcare Leaders Can Learn More
HIMSS is hosting two events in Boston focused on AI for Healthcare. The AI Executive Leadership Summit runs June 24, 2026. The AI in Healthcare Forum follows June 25-26, 2026. Both events require separate registration.
These conferences will cover applications of AI data analysis in clinical settings, including risk stratification and patient assessment tools like FaceAge.
Your membership also unlocks:
